PURPOSE: Very high-risk prostate cancer (PC) is associated with poor response to local and systemic treatments; however, few cases have been molecularly profiled. We studied clinical outcomes and molecular profiles of patients with clinically localized primary Gleason pattern 5 PC. PATIENTS AND METHODS: Clinicopathologic features, targeted somatic and germline sequencing, and PTEN, TP53, and ERG status by immunohistochemistry were assessed in patients undergoing surgery from 2005 to 2015; 60 consecutive patients were identified with Gleason score 5 + 4 = 9 or 5 + 5 = 10 PC after radical prostatectomy with available tissue and clinical follow-up. Clinicopathologic and genomic parameters were correlated with biochemical relapse, metastasis-free survival, time to castration resistance, and overall survival using Cox proportional hazards models. RESULTS: Of patients with somatic sequencing data and clinical follow-up, 34% had DNA repair gene mutations, including 22% (11 of 49) with homologous recombination and 12% (six of 49) with mismatch repair gene alterations. Homologous recombination mutations were germline in 82% (nine of 11) of patients. In addition, 33% (16 of 49) had TP53 mutation, and 51% (29 of 57) had PTEN loss. Overall, 43% developed metastasis, with a time to castration resistance of 12 months. On multivariable analysis of clinicopathologic variables, only ductal/intraductal histology (hazard ratio, 4.43; 95% CI, 1.76 to 11.15; P = .002) and seminal vesicle invasion (hazard ratio, 5.14; 95% CI, 1.83 to 14.47; P = .002) were associated with metastasis. Among genomic alterations, only TP53 mutation and PTEN loss were associated with metastasis on univariable analysis, and neither remained significant in multivariable analyses. These data are retrospective and hypothesis generating. CONCLUSION: Potentially actionable homologous recombination and mismatch repair alterations are observed in a significant proportion of patients with very high-risk PC at the time of radical prostatectomy. These findings could inform the design of prospective trials in this patient population.
PURPOSE: Very high-risk prostate cancer (PC) is associated with poor response to local and systemic treatments; however, few cases have been molecularly profiled. We studied clinical outcomes and molecular profiles of patients with clinically localized primary Gleason pattern 5 PC. PATIENTS AND METHODS: Clinicopathologic features, targeted somatic and germline sequencing, and PTEN, TP53, and ERG status by immunohistochemistry were assessed in patients undergoing surgery from 2005 to 2015; 60 consecutive patients were identified with Gleason score 5 + 4 = 9 or 5 + 5 = 10 PC after radical prostatectomy with available tissue and clinical follow-up. Clinicopathologic and genomic parameters were correlated with biochemical relapse, metastasis-free survival, time to castration resistance, and overall survival using Cox proportional hazards models. RESULTS: Of patients with somatic sequencing data and clinical follow-up, 34% had DNA repair gene mutations, including 22% (11 of 49) with homologous recombination and 12% (six of 49) with mismatch repair gene alterations. Homologous recombination mutations were germline in 82% (nine of 11) of patients. In addition, 33% (16 of 49) had TP53 mutation, and 51% (29 of 57) had PTEN loss. Overall, 43% developed metastasis, with a time to castration resistance of 12 months. On multivariable analysis of clinicopathologic variables, only ductal/intraductal histology (hazard ratio, 4.43; 95% CI, 1.76 to 11.15; P = .002) and seminal vesicle invasion (hazard ratio, 5.14; 95% CI, 1.83 to 14.47; P = .002) were associated with metastasis. Among genomic alterations, only TP53 mutation and PTEN loss were associated with metastasis on univariable analysis, and neither remained significant in multivariable analyses. These data are retrospective and hypothesis generating. CONCLUSION: Potentially actionable homologous recombination and mismatch repair alterations are observed in a significant proportion of patients with very high-risk PC at the time of radical prostatectomy. These findings could inform the design of prospective trials in this patient population.
Authors: Michael S Cookson; Gunnar Aus; Arthur L Burnett; Edith D Canby-Hagino; Anthony V D'Amico; Roger R Dmochowski; David T Eton; Jeffrey D Forman; S Larry Goldenberg; Javier Hernandez; Celestia S Higano; Stephen R Kraus; Judd W Moul; Catherine Tangen; J Brantley Thrasher; Ian Thompson Journal: J Urol Date: 2007-02 Impact factor: 7.450
Authors: Liana B Guedes; Fawaz Almutairi; Michael C Haffner; Gaurav Rajoria; Zach Liu; Szczepan Klimek; Roberto Zoino; Kasra Yousefi; Rajni Sharma; Angelo M De Marzo; George J Netto; William B Isaacs; Ashley E Ross; Edward M Schaeffer; Tamara L Lotan Journal: Clin Cancer Res Date: 2017-04-26 Impact factor: 12.531
Authors: Alcides Chaux; Roula Albadine; Antoun Toubaji; Jessica Hicks; Alan Meeker; Elizabeth A Platz; Angelo M De Marzo; George J Netto Journal: Am J Surg Pathol Date: 2011-07 Impact factor: 6.394
Authors: Rong Na; S Lilly Zheng; Misop Han; Hongjie Yu; Deke Jiang; Sameep Shah; Charles M Ewing; Liti Zhang; Kristian Novakovic; Jacqueline Petkewicz; Kamalakar Gulukota; Donald L Helseth; Margo Quinn; Elizabeth Humphries; Kathleen E Wiley; Sarah D Isaacs; Yishuo Wu; Xu Liu; Ning Zhang; Chi-Hsiung Wang; Janardan Khandekar; Peter J Hulick; Daniel H Shevrin; Kathleen A Cooney; Zhoujun Shen; Alan W Partin; H Ballentine Carter; Michael A Carducci; Mario A Eisenberger; Sam R Denmeade; Michael McGuire; Patrick C Walsh; Brian T Helfand; Charles B Brendler; Qiang Ding; Jianfeng Xu; William B Isaacs Journal: Eur Urol Date: 2016-12-15 Impact factor: 20.096
Authors: Colin C Pritchard; Stephen J Salipante; Karen Koehler; Christina Smith; Sheena Scroggins; Brent Wood; David Wu; Ming K Lee; Suzanne Dintzis; Andrew Adey; Yajuan Liu; Keith D Eaton; Renato Martins; Kari Stricker; Kim A Margolin; Noah Hoffman; Jane E Churpek; Jonathan F Tait; Mary-Claire King; Tom Walsh Journal: J Mol Diagn Date: 2013-11-02 Impact factor: 5.568
Authors: Dan Robinson; Eliezer M Van Allen; Yi-Mi Wu; Nikolaus Schultz; Robert J Lonigro; Juan-Miguel Mosquera; Bruce Montgomery; Mary-Ellen Taplin; Colin C Pritchard; Gerhardt Attard; Himisha Beltran; Wassim Abida; Robert K Bradley; Jake Vinson; Xuhong Cao; Pankaj Vats; Lakshmi P Kunju; Maha Hussain; Felix Y Feng; Scott A Tomlins; Kathleen A Cooney; David C Smith; Christine Brennan; Javed Siddiqui; Rohit Mehra; Yu Chen; Dana E Rathkopf; Michael J Morris; Stephen B Solomon; Jeremy C Durack; Victor E Reuter; Anuradha Gopalan; Jianjiong Gao; Massimo Loda; Rosina T Lis; Michaela Bowden; Stephen P Balk; Glenn Gaviola; Carrie Sougnez; Manaswi Gupta; Evan Y Yu; Elahe A Mostaghel; Heather H Cheng; Hyojeong Mulcahy; Lawrence D True; Stephen R Plymate; Heidi Dvinge; Roberta Ferraldeschi; Penny Flohr; Susana Miranda; Zafeiris Zafeiriou; Nina Tunariu; Joaquin Mateo; Raquel Perez-Lopez; Francesca Demichelis; Brian D Robinson; Marc Schiffman; David M Nanus; Scott T Tagawa; Alexandros Sigaras; Kenneth W Eng; Olivier Elemento; Andrea Sboner; Elisabeth I Heath; Howard I Scher; Kenneth J Pienta; Philip Kantoff; Johann S de Bono; Mark A Rubin; Peter S Nelson; Levi A Garraway; Charles L Sawyers; Arul M Chinnaiyan Journal: Cell Date: 2015-05-21 Impact factor: 41.582
Authors: Tamara L Lotan; Wei Wei; Olga Ludkovski; Carlos L Morais; Liana B Guedes; Tamara Jamaspishvili; Karen Lopez; Sarah T Hawley; Ziding Feng; Ladan Fazli; Antonio Hurtado-Coll; Jesse K McKenney; Jeffrey Simko; Peter R Carroll; Martin Gleave; Daniel W Lin; Peter S Nelson; Ian M Thompson; Lawrence D True; James D Brooks; Raymond Lance; Dean Troyer; Jeremy A Squire Journal: Mod Pathol Date: 2016-05-13 Impact factor: 7.842
Authors: Christopher M Heaphy; Michael C Haffner; Mindy K Graham; David Lim; Christine Davis; Eva Corey; Jonathan I Epstein; Mario A Eisenberger; Hao Wang; Angelo M De Marzo; Alan K Meeker; Tamara L Lotan Journal: Hum Pathol Date: 2020-05-07 Impact factor: 3.466
Authors: Kaushal Asrani; Alba Fc Torres; Juhyung Woo; Thiago Vidotto; Harrison K Tsai; Jun Luo; Eva Corey; Brian Hanratty; Ilsa Coleman; Srinivasan Yegnasubramanian; Angelo M De Marzo; Peter S Nelson; Michael C Haffner; Tamara L Lotan Journal: J Pathol Date: 2021-09-23 Impact factor: 7.996
Authors: Harsimar B Kaur; Thiago Vidotto; Adrianna A Mendes; Daniela C Salles; William B Isaacs; Emmanuel S Antonarakis; Tamara L Lotan Journal: Cancer Immunol Immunother Date: 2021-09-17 Impact factor: 6.630
Authors: Oliver Hommerding; Yves Allory; Pedram Argani; Tarek A Bismar; Lukas Bubendorf; Sofía Canete-Portillo; Alcides Chaux; Ying-Bei Chen; Liang Cheng; Antonio L Cubilla; Lars Egevad; Anthony J Gill; David J Grignon; Arndt Hartmann; Ondrej Hes; Muhammad T Idrees; Chia-Sui Kao; Margaret A Knowles; Leendert H J Looijenga; Tamara L Lotan; Colin C Pritchard; Mark A Rubin; Scott A Tomlins; Theodorus H Van der Kwast; Elsa F Velazquez; Joshua I Warrick; Sean R Williamson; Glen Kristiansen Journal: Pathologe Date: 2021-01-04 Impact factor: 1.011
Authors: Emmanuel S Antonarakis; Tamara L Lotan; Harsimar Kaur; Daniela C Salles; Sanjana Murali; Jessica L Hicks; Minh Nguyen; Colin C Pritchard; Angelo M De Marzo; Jerry S Lanchbury; Bruce J Trock; William B Isaacs; Kirsten M Timms Journal: Clin Cancer Res Date: 2020-07-21 Impact factor: 12.531